Background An emerging literature on behavioural phenotypes has highlighted apparent
associations between autism spectrum disorders (ASDs) or ASD‐related phenomenology …

Abstract Objective Fragile X syndrome (FXS) has been the neurodevelopmental disorder
with the most active translation of preclinical breakthroughs into clinical trials. This process …

BACKGROUND AND OBJECTIVE: Individuals with fragile X syndrome (FXS) are frequently
codiagnosed with autism spectrum disorder (ASD). Most of our current knowledge about …

Abstract Background Fragile X syndrome (FXS) is associated with dysregulated
endocannabinoid signaling and may therefore respond to cannabidiol therapy. Design …

Research on animal models of fragile X syndrome suggests that STX209, a γ-aminobutyric
acid type B (GABAB) agonist, might improve neurobehavioral function in affected patients …

Background Arbaclofen improved multiple abnormal phenotypes in animal models of fragile
X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of …

Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by variable
cognitive impairment and behavioral disturbances such as exaggerated fear, anxiety and …

Autism spectrum disorder (ASD) is a common comorbid condition in people with fragile X
syndrome (FXS). It has been assumed that ASD symptoms reflect the same underlying …

Despite early controversy, it is now accepted that a substantial proportion of children with
fragile X syndrome (FXS) meets diagnostic criteria for autism spectrum disorder (ASD). This …

Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and
numerous potential drug targets have been identified. Yet, current prescribing practices are …